Acetylmuramyl-Alanyl-Isoglutamine
"Acetylmuramyl-Alanyl-Isoglutamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity.
| Descriptor ID |
D000119
|
| MeSH Number(s) |
D09.067.550.050 D09.811.522.050 D12.644.233.050
|
| Concept/Terms |
Acetylmuramyl-Alanyl-Isoglutamine- Acetylmuramyl-Alanyl-Isoglutamine
- Muramyl Dipeptide
- Dipeptide, Muramyl
- Acetylmuramyl Alanyl Isoglutamine
- Alanyl Isoglutamine, Acetylmuramyl
- Isoglutamine, Acetylmuramyl Alanyl
Mur-NAc-L-Ala-D-isoGln- Mur-NAc-L-Ala-D-isoGln
- Mur NAc L Ala D isoGln
- N-Acetylmuramyl-L-Alanyl-D-Isoglutamine
- N Acetylmuramyl L Alanyl D Isoglutamine
- N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide
- N Acetyl Muramyl L Alanyl D Glutamic alpha Amide
|
Below are MeSH descriptors whose meaning is more general than "Acetylmuramyl-Alanyl-Isoglutamine".
Below are MeSH descriptors whose meaning is more specific than "Acetylmuramyl-Alanyl-Isoglutamine".
This graph shows the total number of publications written about "Acetylmuramyl-Alanyl-Isoglutamine" by people in this website by year, and whether "Acetylmuramyl-Alanyl-Isoglutamine" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Acetylmuramyl-Alanyl-Isoglutamine" by people in Profiles.
-
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 2014 Feb; 61(2):238-44.
-
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15; 115(22):5339-48.
-
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20; 23(9):2004-11.
-
Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001 Aug; 15(4):723-40, ix.
-
ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother. 1999 Sep; 48(6):312-20.
-
Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm. 1998 Oct; 13(5):363-8.
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995 Aug; 9(4):927-38.
-
Liposomal MTP-PE: a promising new biologic response modifier. Oncol Nurs Forum. 1995 Jun; 22(5):809-16.
-
Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. J Interferon Cytokine Res. 1995 Jun; 15(6):585-92.
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995 Apr; 18(2):93-9.